Summit Therapeutics SMMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$189.42M+13.6% | -$219.17M+5.4% | -$231.79M+59.0% | -$565.71M-799% | -$62.91M-2.8% | ||
| $44K+4.8% | $42K0.0% | $42K+13.5% | $37K+48.0% | $25K+13.6% | ||
| $72.79M-34.9% | $111.78M-14.5% | $130.76M-72.7% | $478.78M+4,215% | $11.1M+0.7% | ||
| $6.8M— | —— | —— | $17.93M+4,937% | $356K-76.7% | ||
| $12.22M+121% | $5.53M+486% | $945K-80.5% | $4.84M+200% | $1.61M-29.3% | ||
| $1.03M+111% | -$9.39M-1,197% | $856K-62.0% | $2.25M+58.8% | $1.42M-85.6% | ||
| -$33K— | $0-100% | $30K+11.1% | $27K+8.0% | $25K0.0% | ||
| -$122.29M-20.0% | -$101.94M-9.5% | -$93.08M-39.5% | -$66.74M-9.1% | -$61.17M-25.7% | ||
| $245K+49.4% | $164K+131% | $71K— | $0-100% | $422K+2,914% | ||
| $177.29M-63.4% | $484.99M— | $0— | $0— | $0-100% | ||
| $177.29M— | —— | —— | $150.81M-6.1% | $160.53M-31.1% | ||
| -$238K+100.0% | -$485.16M-683,220% | -$71K-100% | $150.81M-5.8% | $160.11M— | ||
| $3.8M+272% | $1.02M-50.2% | $2.05M+263% | $565K-72.0% | $2.02M+307% | ||
| $3.8M-99.3% | $573.82M+1,597% | $33.81M+1,422% | $2.22M-71.1% | $7.68M— | ||
| -$19K— | —— | $22K-63.9% | $61K+60.5% | $38K+135% | ||
| -$118.75M— | —— | —— | $86.35M-19.0% | $106.66M+862% | ||
| $4.22M+39.8% | $3.02M— | $0-100% | $1.02M-65.5% | $2.97M— | ||
| $44K+4.8% | $42K0.0% | $42K+13.5% | $37K+48.0% | $25K+13.6% | ||
| -$190K— | —— | —— | $239K+6.7% | $224K— | ||
| -$7.85M-298% | $3.96M— | —— | —— | -$7.59M-288% | ||
| $365K+36.7% | $267K— | —— | —— | $25K— | ||
| -$1.14M— | —— | $476K— | —— | -$1.05M— | ||
| -$33K— | $0-100% | $30K+11.1% | $27K+8.0% | $25K0.0% | ||
| $11.01M+1,012% | -$1.21M+67.7% | -$3.74M-294% | $1.93M+204% | -$1.85M-122% | ||
| $177.29M-63.4% | $484.99M— | $0— | $0— | $0-100% | ||
| $177.29M— | —— | —— | $150.81M-6.1% | $160.53M-31.1% | ||
| $3.8M+272% | $1.02M-50.2% | $2.05M+263% | $565K-72.0% | $2.02M+307% | ||
| $0— | —— | —— | $1.66M-70.7% | $5.66M+1,038% | ||
| $746K+487% | $127K+38.0% | $92K+27.8% | $72K— | $0— | ||
| -$122.54M-20.0% | -$102.1M-9.6% | -$93.15M-39.6% | -$66.74M-8.4% | -$61.59M-26.5% | ||
| -$122.54M-20.0% | -$102.1M-9.6% | -$93.15M-39.6% | -$66.74M-8.4% | -$61.59M-26.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.